Search
Tacrolimus
go.drugbank.com/drugs/DB00864ApprovedInvestigationalTacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. … It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide.
Categories: Agents for Dermatitis, Excluding Corticosteroids, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: Envarsus Pa, PROGRAF CONCENTRATE FOR INFUSION 5 mg/mlSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalSunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. … For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: Sunitinib 1A Pharma 12,5 mg - Hartkapseln, Sunitinib 1A Pharma 25 mg - HartkapselnTrolamine
go.drugbank.com/drugs/DB13747ApprovedInvestigationalTrolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines. … It is commonly used as a pH adjuster and surfactant in industrial and cosmetic products such as skin and hair conditioning products.
Categories: Preparations for Treatment of Wounds and UlcersBazedoxifene
go.drugbank.com/drugs/DB06401ApprovedInvestigationalBazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. … In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis.
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigational[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.
Synonyms: L-sepiapterinInbakicept
go.drugbank.com/drugs/DB16479InvestigationalBCG) immunotherapy; however, NMIBC is associated with a risk of disease recurrence or progression into advanced disease despite initial treatment with BCG. … It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components.
Categories: Experimental Unapproved Treatments for COVID-19Esterified estrogens
go.drugbank.com/drugs/DB09381ApprovedEsterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the … Esterified estrogens contain a mixture of estrogenic substances; the principle component is estrone.
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnEthchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.
Corticorelin ovine triflutate
go.drugbank.com/drugs/DB09067ApprovedIt provides a differential diagnosis for Cushing's disease (a pituitary source of ACTH excess) or of ectopic ACTH syndrome (an ectopic source of ACTH excess). … It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion.
Categories: Tests for Pituitary FunctionTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options. … to be approved for this specific patient population.